Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?

Key Takeaways OPKO Health targets 30% fiscal 2026 growth, backed by RAYALDEE and pipeline momentum.RAYALDEE generated $21.0M in sales in first nine months of 2025, supported by broad U.S. distributioOPK advances Phase 1/2 trials and expands deals with Entera, Regeneron and Merck.OPKO Health, Inc. (OPK) is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff comp ...